- Company
- Anti-depressant Brintellix generic for exclusivity succeeded
- by Jan 20, 2023 06:07am
- Myungin Pharmaceutical (CEO Lee Dong-myung) and Unimmed Pharmaceutical (CEO Kim Gun-nam) announced on the 18th that they succeeded in invalidating the patent for the antidepressant Brintellix. The Korean Intellectual Property Tribunal recently made a decision to cite the claim on Brintellix purpose patents filed by both companies against Lund
- Company
- The Brain disease prescription market disappears
- by Chon, Seung-Hyun Jan 19, 2023 05:59am
- Pharmaceutical companies lost 30 billion won a year due to Oxiracetam. Prescription loss became a reality as it failed to prove its efficacy in an eight-year clinical re-evaluation. Following acetyl-L-Carnitin last year, the annual prescription market worth 100 billion won has disappeared due to the failure of clinical re-evaluation of cerebr
- Company
- Generic drugs occupy 41% of antidiabetics market in 9 mths
- by Kim, Jin-Gu Jan 19, 2023 05:58am
- Generic products of off-patent drugs are quickly increasing their influence In the DPP-4 inhibitor class antidiabetic drug market. The market share held by generic versions of the original Galvus (vildagliptin) that were launched after the patent expiry of the original drug in March last year increased to 41% at the end of last year. The
- Company
- Paclitaxel copyright transfer
- by Kim, Jin-Gu Jan 19, 2023 05:58am
- The domestic copyright of Paclitaxel anticancer drugs has shifted one after another. Samyang Biopharmaceuticals' Genexol, the No. 1 item in the market, will be jointly sold by HK inno.N instead of Boryung. Boryung will jointly sell BMS Taxol, the original product, for the first time in seven years instead of Genexol. The annual sales of the t
- Company
- The Canadian gov. has put the drug price system on hold
- by Kim, Jin-Gu Jan 18, 2023 06:04am
- Korea to add Canada to drug price reference country this year...The domestic drug price reduction variable disappears. The reorganization of the drug price system, which was promoted by the Canadian government, has been temporarily suspended. Analysts say that the Canadian Ministry of Health officially announced that it would come up with a n
- Company
- Biktarvy, applies to the expansion of pediatric indications
- by Eo, Yun-Ho Jan 18, 2023 06:04am
- HIV treatment Biktarvy is aiming to expand pediatric indications in Korea. According to related industries, Gilead Science Korea recently submitted an application to expand indications for pediatric patients who weigh at least 14kg to 25kg of the HIV compound Biktarvy and have no experience in antiretroviral treatment or have been suppressed
- Company
- Curing terminal cancer without treatment options
- by Jan 17, 2023 06:02am
- Mr. A, a 60-year-old Korean male patient, was diagnosed with gastric cancer several years ago. After struggling to treat the disease for several years, the hospital told A that there was no other treatment option available for him and that he may not be able to live for more than 6 months. As a last resort, A registered to enroll in the KOSM
- Company
- Despite the largest export of diagnostic kits ever, we canno
- by Kim, Jin-Gu Jan 17, 2023 06:02am
- Exports of domestic diagnostic kits broke the record last year. However, export performance in the second half of the year is on the decline. Analysts say that as the global COVID-19 situation calms down, exports of diagnostic kits, which have been on a high march, are returning to the level of previous years. According to the Korea Customs S
- Company
- Stelara biosimilar of Dong-A ST succeeded in clinical trials
- by Chon, Seung-Hyun Jan 17, 2023 06:02am
- Dong-A ST announced on the 16th that the Stelara biosimilar DMB-3115 has confirmed its safety and effectiveness in clinical trials. On the same day, Dong-A ST introduced the results of DMB-3115's global phase 3 clinical trial top line and announced that it would apply for item permission to the U.S. and European health authorities in the first h
- Company
- Novartis charged with 'rebate' has been fined
- by jung, sae-im Jan 16, 2023 07:47pm
- Novartis and Media Fines…Suspension of imprisonment for those involved Novartis Korea, accused of providing illegal rebates of about 2.6 billion won to doctors, was finally fined by the Supreme Court. On the 12th, the Supreme Court rejected the appeal filed by Novartis Korea, related parties, and media outlets who were convicted in the o
